US Patent
US9241948 — Ready to be infused gemcetabine solution
Formulation · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2033-07-01 · 7y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects a large volume infusion dosage form of gemcitabine, a stable solution ready to be infused.
USPTO Abstract
A large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion container, wherein the solution is ready-to-be-infused.
Drugs covered by this patent
- Gemzar (Gemcitabine Hydrochloride) · Accord Hlthcare
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.